Moderna saw the highest growth of 1.22% in patent filings and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.74%. GlobalData’s DataBook provides a comprehensive analysis of Moderna‘s patent filings and grants. Buy the databook here.
Moderna has been focused on protecting inventions in United States(US) with 20 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 39% filings and 22% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Japan(JP) patent Office are among the top ten patent offices where Moderna is filings its patents. Among the top granted patent authorities, Moderna has 33% of its grants in European Patent Office(EPO), 22% in United States(US) and 22% in Japan(JP).
Arbutus Biopharma and Sanofi could be the strongest competitors for Moderna
Patents related to nanomedicine and rare diseases lead Moderna's portfolio
Moderna has the highest number of patents in nanomedicine followed by, rare diseases and climate change. For nanomedicine, nearly 59% of patents were filed and 62% of patents were granted in Q2 2024.
Petrochemicals related patents lead Moderna portfolio followed by severe acute respiratory syndrome (sars), and human metapneumovirus infections
Moderna has highest number of patents in petrochemicals followed by severe acute respiratory syndrome (sars), human metapneumovirus infections, bleeding and clotting disorders, and wounds. For petrochemicals, nearly 6% of patents were filed and 3% of patents were granted in Q2 2024.
For comprehensive analysis of Moderna's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.